ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO334

Effects of a Vascular Endothelial Protein Tyrosine Phosphatase (VE-PTP) Blocking Antibody in a Mouse Model of Severe Diabetic Kidney Disease

Session Information

Category: Diabetic Kidney Disease

  • 701 Diabetic Kidney Disease: Basic

Authors

  • Rana, Rajashree, Janssen Research and Development LLC, Boston, Massachusetts, United States
  • Natoli, Thomas A., Janssen Research and Development LLC, Cambridge, Massachusetts, United States
  • Khandelwal, Puneet, Janssen Research and Development LLC, Spring House, Pennsylvania, United States
  • Pissios, Pavlos, Janssen Research and Development LLC, Boston, Massachusetts, United States
  • Muhammad, Abdul Bari, Janssen Research and Development LLC, Cambridge, Massachusetts, United States
  • Chipashvili, Vaja, Janssen Research and Development LLC, Cambridge, Massachusetts, United States
  • Farrington, Krista P., Janssen Research and Development LLC, Cambridge, Massachusetts, United States
  • Zhou, Wen, Janssen Research and Development LLC, Cambridge, Massachusetts, United States
  • Zheng, Gang, Janssen Research and Development LLC, Boston, Massachusetts, United States
  • Bukanov, Nikolay O., Janssen Research and Development LLC, Boston, Massachusetts, United States
  • Magnone, Maria Chiara, Janssen Research and Development LLC, Boston, Massachusetts, United States
Background

Diabetic Kidney Disease (DKD) is a disease with complex pathophysiology wherein endothelial dysfunction plays a central role in disease formation and progression. Emerging evidence emphasizes the critical role of the Tie-2 receptor and Angiopoietin 1 and 2 ligands in DKD. Tie-2 signaling is negatively regulated by the endothelial specific transmembrane Vascular Endothelial Protein Tyrosine Phosphatase (VE-PTP). Recently, it has been reported that the genetic deletion of VE-PTP provided protection from hypertension and diabetes induced renal injury in a mouse model of DKD. In the current study we investigated the efficacy of VE-PTP inhibition in a mouse model of severe DKD with an extracellular domain (ECD) targeting VE-PTP blocking antibody.

Methods

VE-PTP blocking antibody was characterized in vitro, in vivo in dermal vascular permeability assays, and in pharmacokinetic experiments. The in vivo proof-of-concept experiment with the VE-PTP blocking antibody and standard of care lisinopril were performed in hypertensive diabetic mice. Renin overexpression (AAV) was used to induce hypertension in db/db mice following uninephrectomy (Unx). Treatment was initiated 4-weeks after renin AAV administration and continued for another 4 weeks.

Results

Our results showed that VE-PTP inhibition with an ECD targeting VE-PTP antibody induced Tie2-phosphorylation and provided protection against VEGF-A induced vascular permeability both in vitro and in vivo. Furthermore, treatment with the VE-PTP antibody resulted in decreased kidney gene expression of endothelial activation markers (Angpt2, Edn1, Icam1 and Vcam1). However, the VE-PTP blocking antibody treatment did not alter urinary albumin-to-creatinine ratio (uACR) in a severe mouse model of DKD.

Conclusion

VE-PTP inhibition with an ECD targeting antibody did not ameliorate hypertension- and diabetes-induced albuminuria in a preclinical mouse model of DKD.

Funding

  • Commercial Support – Janssen Pharmaceuticals, Johnson & Johnson